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Editor's Note
Regulatory T Cells
Stefan Beissert1, Agatha Schwarz2 and Thomas Schwarz2
Immunologic self-tolerance is critically dependent on the induction but also on the downregulation of immune 
responses. Though ignored and neglected for many years, suppressor T cells, now renamed regulatory T cells 
(Tregs), play an important role in the negative regulation of immune responses. Several subsets of Tregs have been 
described. Naturally occurring CD4+CD25+ Tregs are important in the prevention of autoimmune diseases. Type 
1 Tregs, another subtype of Treg that is inducible, exert their suppressive activity primarily via the release of IL-10. 
Detailed knowledge about the phenotype and mode of action of these cells will signifi cantly increase our under-
standing of the pathogenesis of autoimmune diseases and will also help to identify new therapeutic strategies.
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Every physiologic process needs to be 
controlled and to be turned down after 
completion of its mission. Without 
downregulation, physiologic processes 
are at high risk of becoming patholog-
ic. Hence, downregulation is of utmost 
importance. This applies in particular 
to immune reactions. Immunologic 
downregulation brings immune 
responses to an end. For a long time, 
immunologists were primarily interest-
ed in the cellular and molecular mech-
anisms underlying the induction of an 
immune reaction, whereas the mecha-
nisms of negative control were almost 
ignored. However, in the past decade, 
negative regulation has gained atten-
tion as it has become recognized as a 
gateway to the understanding of auto-
immunity. Among several hypotheses, 
one generated by Gershon et al. in the 
early 1970s suggested that a subset of 
T cells may exert suppressive activity, 
and the term “suppressor cells” was 
coined to describe these (Gershon 
et al., 1972). However, at that time 
neither the cells nor the postulated 
soluble factors released by these cells 
could be convincingly characterized. 
Therefore, the entire concept was criti-
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In the early 1970s, Coombs found that sheep red blood 
cells (SRBCs) were able to bind to a distinct population 
of human lymphocytes. The SRBCs were found to bind 
to the majority of thymocytes but not to Ig-bearing 
lymphocytes. The ability of SRBCs to form “rosettes” 
was an early marker of the T-cell subset of human 
lymphocytes. Over the past 30 years, the development 
of numerous markers of T cells has allowed the 
identification and characterization of distinctive T-cell 
subsets that function in unique ways both in the normal 
immune response and in immune-mediated disease.
In this month’s Perspectives series, the recent advances 
of our understanding of three critical T-cell subsets are 
presented. T cells play an important role in the regulation 
of the immune response and the prevention of the 
development of autoimmunity. Beissert, Schwarz, and 
Schwarz discuss a subset of T cells that provide critical 
regulation of many aspects of the immune response, 
regulatory T cells (Treg). The importance of developing 
vaccines against new infectious agents as well as 
numerous cancers has led to a continued interest in the 
role of cytotoxic T cells in the immune response. 
In the second article, Girardi describes a unique 
subset of T cells, γδ T cells, that are enriched at 
epithelial surfaces and may play a critical role in both 
immunoregulation and immunosurveillance.
In the final article in this series, Andersen and co-
authors provide an update on the basic mechanisms 
of action of cytotoxic T cells and their role in both the 
pathogenesis and the treatment of disease.
These three outstanding contributions to the 
Perspectives series will provide the reader with the 
necessary background to keep abreast of this important 
and rapidly advancing area of immunology.
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cized, and even the existence of sup-
pressor T cells was drawn into question 
(Janeway, 1988). Despite these adverse 
circumstances, several experiments 
were performed that gave clear indica-
tions that such cells may indeed exist. 
Strong support for the concept of sup-
pressor T cells came from the field of 
photoimmunology, as it was clearly 
demonstrated that antigen-specific 
suppression can be adoptively trans-
ferred by injection of T cells (Elmets et 
al., 1983; Fisher and Kripke, 1978).
The whole concept of suppression 
and suppressor cells was revived by 
a few papers published in the mid-
1990s (Jonuleit and Schmitt, 2003). 
One, appearing in Nature, reported 
that antigen-specific T-cell clones sup-
pressed the proliferation of CD4+ T cells 
in response to antigen and prevented 
colitis in a severe combined immu-
nodeficiency mouse model (Groux et 
al., 1997). These cells were designated 
type 1 regulatory T cells (Tr1 cells) and 
presented as cells that suppress anti-
gen-specific immune responses and 
actively downregulate a pathologic 
immune response in vivo. Two years 
earlier it had been proposed that CD4+ 
T cells that in addition express the 
IL-2 receptor α chain (CD25) control 
autoreactive T cells in vivo (Sakaguchi 
et al., 1995). These studies finally 
resulted in the identification of a 
population, now called CD4+CD25+ 
suppressor/regulatory T cells, that is 
anergic but also suppressive (Takahashi 
et al., 2000; Thornton et al., 2004b). A 
third subset of T cells was described 
that suppressed the proliferation of T-
cell clones in a transforming growth 
factor-β (TGF-β)-dependent manner 
(Chen et al., 1994). These cells were 
called T helper type 3 (Th3) cells. Thus 
several subtypes were identified within 
a cell population whose very existence 
had been denied just before (Table 1). 
This heterogeneity may be partially 
blamed for the initial confusion and 
failure to characterize these cells in the 
1970s and 1980s. In addition, it may 
not be surprising if further subtypes 
are detected in the future. Because of 
this history, the terms “suppressor T 
cells” and “regulatory T cells” (Tregs) 
are sometimes used interchangeably. 
The term “Treg” is preferred by most 
researchers, probably because of a still 
existing historical stigma against the 
term “suppressor cells.” Irrespective of 
which term is used, it is important to 
clearly define to which type of regula-
tory or suppressor T cells one refers. 
This review will primarily focus on 
CD4+CD25+ Tregs and Tr1 cells.
CD4+CD25+ Regulatory T Cells
In 1995, Sakaguchi and co-workers 
described in mice a population of 
naturally occurring CD4+CD25+ T 
cells that constituted approximately 
5–10% of all T helper (Th) cells. These 
CD4+CD25+ T cells exhibited potent 
regulatory functions both in vitro and in 
vivo (Sakaguchi et al., 1995; Sakaguchi 
et al., 2001). Injection of CD4+CD25– T 
cells into mice with severe combined 
immunodeficiency induced colitis, 
whereas co- injection of CD4+CD25+ 
together with CD4+CD25– T cells pre-
vented bowel inflammation. In culture, 
murine CD4+CD25+ T cells suppressed 
the proliferation of CD4+CD25– T cells 
or CD8+ T cells, proving that these 
cells are suppressive both in vivo and 
in vitro (Piccirillo and Shevach, 2001). 
A similar population of T cells with a 
comparable phenotype was identi-
fied in humans (Dieckmann et al., 
2001; Jonuleit et al., 2001). From these 
results it was concluded that natural 
CD4+CD25+ T cells play an important 
role in the suppression of autoimmune 
responses via inhibition of self-reactive 
T cells. 
Phenotypic and functional charac-
terization of CD4+ CD25+ regulatory 
T cells. A classical characteristic of 
CD4+CD25+ T cells is their lack of pro-
liferative response upon TCR activation 
or stimulation with mitogenic antibod-
ies. Thus, an anergic phenotype is attrib-
uted to these cells. CD4+CD25+ T cells 
Table 1. Subsets of natural and induced regulatory T cells1
Treg subset Regulatory mechanisms Transcription factor expressed Target cells Function 
CD4+CD25+ Tregs Cell contact-dependent, 
cytokines (IL-10?2) 
Foxp3 T cells, APCs Suppression of autoimmunity; 
inhibition of allograft rejection and 
of immune responses induced by 
microbial infection; mediation of 
UV-induced immunosuppression 
CD4+CD25– Tregs Mostly mediated by cytokines Foxp3 (?2) T/B cells, APCs Suppression of autoimmunity 
Tr1 cells Mediated by IL-10 Foxp3 (?2) T cells Suppression of autoimmunity 
Th3 cells Mediated by TGF-β ?2 T cells Suppression of autoimmunity 
NKTregs IL-4, IL-10, TGF-β, cytotoxicity ?2 T cells, APCs, tumor cells Elimination of tumors and patho-
gens; suppression of autoimmunity; 
mediation of UV-induced suppres-
sion of protective tumor immunity 
CD8+ Tregs Cell contact-dependent, 
cytotoxicity, cytokines (?2) 
Foxp3 (?2) T cells Suppression of autoimmunity; 
regulation of peripheral TCR 
repertoire 
CD8+CD28– Tregs Induction of ILT3/ILT4 in DCs Foxp3 (?2) DCs/APCs Regulation of autoimmunity (?b) 
1Subsets have been detected in humans and rodents. 2Issue uncertain, not yet clear or not yet investigated. Abbreviations: APC, antigen-presenting cell; 
DC, dendritic cell; ILT, immunoglobulin transcript; NKTreg, regulatory cell of natural killer T cell phenotype; Th3, T helper type 3; Tr1 cell, type 1 regula-
tory T cell; Treg, regulatory T cell.
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depend on exogenous IL-2 but inhibit 
the transcription of IL-2 in conventional 
CD25– T cells (Shevach, 2002; Thornton 
et al., 2004a). The suppressor phenotype 
requires in vitro cell contact between 
murine CD4+CD25+ and CD4+CD25– T 
cells and appears to be mediated at 
least in part by granzyme B (Gondek et 
al., 2005). Whether cell contact-depen-
dent mechanisms are required for sup-
pressor activity in humans and rodents 
in vivo is currently under investiga-
tion in many laboratories. From studies 
using antigen-specific mouse models, it 
is clear that CD4+CD25+ T cells have to 
be activated via their TCR to exert their 
inhibitory function. However, there is 
experimental evidence that, once acti-
vated, Tregs inhibit effector T cells in an 
antigen-nonspecific way (Thornton and 
Shevach, 2000). Subsequent studies in 
mice have suggested that CD4+CD25+ 
T cells play a role in the suppression of 
responses to viral, bacterial, and pro-
tozoal infections (Sakaguchi, 2003). 
Additionally, CD4+CD25+ T cells were 
found to suppress protective antitumor-
al immunity (Wang et al., 2004). In turn, 
blocking Treg function with a neutral-
izing antibody against cytotoxic T lym-
phocyte-associated antigen 4 (CTLA-
4) induced an increase in protective 
immune responses (Loser et al., 2005a).
A number of caveats preclude the 
use of CD25 as a unique marker of 
Tregs. CD25 is transiently expressed 
upon activation of murine Th cells, 
and its expression is very dynamic 
(Annacker et al., 2001). Notably, 
peripheral CD4+CD25– T cells also pos-
sess some suppressor activity, which, 
however, is less potent than that of their 
CD4+CD25+ counterparts. Accordingly, 
injections of T-cell populations that 
were depleted of CD25+ cells were 
able to prevent the development of 
experimental allergic encephalomy-
elitis (EAE) in a myelin basic protein 
(MBP)-specific TCR transgenic mouse 
model (Olivares-Villagomez et al., 
2000). The CD4+CD25+ T-cell popula-
tion appears to be heterogeneous, and 
it is assumed that only a part of this 
quite uncharacterized population exerts 
regulatory/suppressive activity, such as 
CD4+CD25high cells. In addition, it is 
quite clear that not all T cells that exert 
suppressive activity express CD25. 
This has sparked the identifica-
tion of a number of surface molecules 
associated with human and/or murine 
Tregs, such as intracellular cytotoxic T-
lymphocyte activation antigen (CTLA-
4; CD152) (Read et al., 2000; Salomon 
et al., 2000), neuropilin-1 (Nrp-1) 
(Bruder et al., 2004), glucocorti-
coid-induced tumor necrosis factor 
family-related receptor (McHugh et al., 
2002), the chemokine receptors CCR4 
and CCR8 (Iellem et al., 2001), CD62L 
(L-selectin) (Salomon et al., 2000), 
lymphocyte activation gene-3 (LAG-3) 
(Huang et al., 2004), and integrin αEβ7 
(CD103) (Lehmann et al., 2002). Some 
of these molecules have been shown to 
be important for the suppressor func-
tion of Tregs in the murine system. 
Another of their characteristics is the 
low expression of CD45RB (Read et 
al., 1998).
Murine CD4+CD25+ T cells that con-
stitutively express CTLA-4 can affect 
tryptophan metabolism in dendritic 
cells (DCs) (Fallarino et al., 2003). This 
process requires B7 expression on DCs 
and cytokine production. CD4+CD25+ 
T cells induce activation of indolamine 
2,3-dioxygenase in DCs. Indolamine 
2,3-dioxygenase, which is under tran-
scriptional control of IFN-γ, catalyzes 
the initial and rate-limiting step of tryp-
tophan degradation, resulting in tryp-
tophan deficiency. Because tryptophan 
is an essential proliferative stimulus for 
effector T cells, these cells undergo 
apoptosis in a tryptophan-deprived 
environment (Figure 1). Studies per-
formed with B7- and/or IFN-γ-defi-
cient mice revealed that the release of 
IFN-γ by DCs is a major mechanism by 
which activated CD4+CD25+ T cells 
modulate indolamine 2,3-dioxygen-
ase expression in those cells, but IFN -
γ release by activated CD4+CD25+ T 
cells can additionally contribute to the 
regulation of tryptophan metabolism. 
These findings provide a new view of 
indolamine 2,3-dioxygenase-based 
immunoregulation that combines the 
regulatory function of Tregs with DCs 
acting as the final mediators of tolero-
genic responses.
More recently, gene expression pro-
filing showed high expression of LAG-
3 in CD4+CD25+ T cells (Bruder et al., 
2004; Huang et al., 2004). LAG-3 is a 
CD4-related molecule that binds major 
histocompatibility complex class II. 
Natural CD4+CD25+ T cells expressed 
LAG-3 upon activation and in the pres-
ence of effector T cells. Suppressor 
activity of CD4+CD25+ T cells was 
inhibited by anti-LAG-3 antibodies, and 
CD4+CD25+ T cells isolated from LAG-
3–/– mice displayed reduced suppressor 
capacity. In summary, LAG-3 appears 
to be a promising molecule suitable for 
the characterization of Tregs.
Besides influencing DCs, CD4+CD25+ 
T cells can convey suppressor activity 
to conventional CD4+ Th cells, a phe-
nomenon consequently called infec-
tious tolerance (Gershon and Kondo, 
1971; Jonuleit et al., 2002). Human 
CD4+ T cells that had been co-cultured 
with CD4+CD25+ T cells after isolation 
were able to suppress the proliferation 
of freshly prepared conventional CD4+ 
T cells. This “infectious” suppressor 
function, transferred from CD4+CD25+ 
T cells, was cell contact-dependent and 
partially mediated by TGF-β (Jonuleit 
et al., 2002). However, there are first 
indications that CD4+CD25+ Tregs can 
CTLA-4 IDO
kynurenine
tryptophan
tryptophan
apoptosis
CD80/86
Treg
Teff
DC
Figure 1. Regulatory T cells inhibit effector 
T cells via induction of indolamine 2,3-
dioxygenase. Regulatory T cells (Tregs) induce 
activation of indolamine 2,3-dioxygenase (IDO) 
in dendritic cells (DCs). This is partially mediated 
via the interaction of cytotoxic T lymphocyte-
associated antigen 4 (CTLA-4) expressed on 
Tregs and CD80/86 expressed on DCs. IDO 
catalyzes the initial and rate-limiting step of 
tryptophan degradation, resulting in tryptophan 
deficiency. Because tryptophan is an essential 
proliferative stimulus for effector T cells (Teff), 
these cells undergo apoptosis in a tryptophan-
deprived environment.
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mediate their suppressor activity also 
via the release of IL-10.
The balance between the functions 
of Tregs and effector T cells appears 
also to be relevant to the pathogenesis 
of inflammatory disorders in humans. 
In psoriasis, it was found that a CD4+ 
T-lymphocyte sub-population in peri-
pheral blood, phenotypically resem-
bling Tregs (CD25high, CTLA-4+, 
Foxp3high), was deficient in its sup-
pressor activity. This was associated 
with accelerated proliferation of 
CD4+ responder T cells in psoriasis 
(Sugiyama et al., 2005). A similar dys-
function could be detected in Tregs 
isolated from psoriatic plaques. Thus, 
it is speculated that this dysfunction 
both in the skin and in the blood of 
psoriatic patients may cause hyperp-
roliferation of psoriatic pathogenic T 
cells in vivo.
In addition, numbers of CD4+CD25+ 
T cells were found to be significant-
ly increased in patients with atopic 
dermatitis compared with asthmatic 
patients or non-atopic healthy con-
trol subjects. These cells effectively 
suppressed proliferative responses 
of CD4+CD25– cells after anti-CD3 
stimulation. In contrast, after stimula-
tion with staphylococcal enterotoxin 
B, CD4+CD25+ cells were no longer 
anergic and had lost their suppressive 
activity (Ou et al., 2004). This indi-
cates that patients with atopic derma-
titis have significantly increased num-
bers of peripheral blood Tregs with 
normal immunosuppressive activ-
ity. However, after stimulation with 
staphylococcal antigens, Tregs lose 
their immunosuppressive activity. This 
suggests a novel mechanism by which 
staphylococci may augment T-cell acti-
vation in atopic patients. In addition, 
it was recently shown that cutaneous 
T-cell lymphoma cells adopt a Treg 
phenotype, expressing CD25/CTLA-
4 and Foxp3 and secreting IL- 10 and 
TGF-β (Berger et al., 2005). Cutaneous 
T-cell lymphoma Tregs suppress nor-
mal T-cell antigen-driven secretion 
of IL-2 and IFN-γ. This suggests that 
conversion of cutaneous T-cell lym-
phoma cells to Tregs may explain the 
anergic, immunosuppressive nature of 
this malignancy in its advanced stage. 
On the other hand, it might also be 
possible that cutaneous T-cell lympho-
ma cells derive directly from patho-
genic Treg clones, a hypothesis that 
needs to be proven in the future.
Development of naturally occur-
ring CD4+CD25+ regulatory T cells. 
Naturally occurring CD4+CD25+ T 
cells are thymus-derived, as thymec-
tomy at day 3 of life results in low 
to undetectable numbers of peri-
pheral CD4+CD25+ T cells in BALB/c 
mice (Sakaguchi et al., 1995). CD25 
expression is acquired relatively late 
by CD4+CD8– single-positive thymo-
cytes in humans and rodents. These 
cells can inhibit T-cell proliferation 
and the development of inflamma-
tory bowel disease as well as diabe-
tes in mice (Sakaguchi et al., 2001). 
Therefore, an important role in the 
prevention of autoimmunity was 
attributed to these cells. From grafting 
studies it was concluded that thymic 
epithelium is involved in the differen-
tiation of Tregs. Grafting of allogeneic 
thymic epithelium induced tolerance 
to a variety of peripheral tissue of 
donor origin that was mediated by and 
transferable with CD4+ T cells (Maloy 
and Powrie, 2001). Especially, corti-
cal major histocompatibility complex 
class II-positive thymic epithelial cells 
appear to play a key role in the posi-
tive selection of CD4+CD25+ T cells 
(Bensinger et al., 2001). Interestingly, 
thymocytes expressing a low-
affinity TCR with known specific-
ity do not develop into Tregs (von 
Boehmer and Jaeckel, 2001). These 
data led to the hypothesis that thymo-
cytes that develop into Tregs would 
have to express a TCR with relatively 
high affinity to self-peptides, whereas 
lower-affinity interactions between 
TCR and self-peptides expressed on 
thymic antigen-presenting cells (APCs) 
would promote the development of 
conventional CD4+CD25– T cells. In 
turn, extremely high-avidity interac-
tions would lead to clonal deletion, 
as demonstrated in other transgenic 
models. In this scheme, a rather nar-
row window for the selection of Tregs 
would ensure that they represent only 
a small proportion of positively select-
ed cells, perhaps just enough to main-
tain self-tolerance in the periphery.
Transcription factors play an impor-
tant role in the development and lin-
eage commitment of T cells. T-bet has 
been shown to control Th type 1 (Th1) 
cells, and GATA-3 to control Th type 
2 (Th2) cells (Finotto and Glimcher, 
2004). More recently, analysis of the 
genetic defects in patients and mice 
suffering from a similar X-linked reces-
sive autoimmune and inflammatory 
disorder revealed mutations in a com-
mon gene called Foxp3 (Wildin et al., 
2001). Foxp3 encodes a member of 
the forkhead/winged-helix family of 
transcription regulators, termed scur-
fin (also known as forkhead box P3) 
(Brunkow et al., 2001). In patients suf-
fering from the immune dysregulation, 
polyendocrinopathy, enteropathy, X-
linked (IPEX) syndrome (MIM 304930), 
mutations in the Foxp3 gene have 
been identified (Bennett et al., 2001). 
These mutations affected the fork-
head/winged-helix domain of the scur-
fin protein, which is needed for DNA 
interactions. The genetic equivalent to 
IPEX syndrome is the scurfy (sf) mouse. 
Scurfy is an X-linked recessive mouse 
mutant strain that results in a rapidly 
fatal lymphoproliferative disorder char-
acterized by excessive proliferation of 
CD4+ T cells and extensive multiorgan 
infiltration (Brunkow et al., 2001). A 
similar phenotype has been reported in 
mice with a gene-targeted disruption 
of Foxp3 (Fontenot et al., 2003). These 
studies prompted investigations on 
the role of Foxp3 during development 
of Tregs. Indeed, natural CD4+CD25+ 
T cells could not be detected in 
Foxp3–/– or sf mice (Fontenot et al., 
2003; Khattri et al., 2003). Moreover, 
natural CD4+CD25+ Tregs were found 
to express high levels of Foxp3 (Hori 
et al., 2003). Overexpression of Foxp3 
in T cells induced a suppressor phe-
notype and expansion of CD4+CD25+ 
T cells (Fontenot et al., 2003; Hori et 
al., 2003; Khattri et al., 2003; Loser et 
al., 2006). These findings indicate that 
Foxp3 represents a key transcription 
factor in the development of natural 
CD4+CD25+ Tregs.
Parallel to Foxp3, family members 
of nuclear factor of activated T cells 
(NFAT) are also involved in Treg–
effector T cell interactions. Recently, 
it was shown that mice deficient in 
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NFATc2 and NFATc3 develop a mas-
sive lymphadenopathy and autoim-
munity. CD4+CD25+ T cells from these 
double-deficient (NFATc2/NFATc3–/–) 
mice lacked suppressor activity, with 
the exception of a small subset of CD4+ 
T cells expressing high levels of CD25 
and glucocorticoid-induced tumor 
necrosis factor family-related recep-
tor (Bopp et al., 2005). Interestingly, 
neither wild-type CD4+CD25+ T cells 
nor CD4+CD25+ T cells from double-
deficient mice were able to suppress 
the proliferation of CD4+CD25– T cells 
from double-deficient mice. From these 
results it was concluded that NFATc2/
NFATc3 deficiency is compatible with 
the development of CD4+CD25+ T cells 
but renders conventional CD4+ T cells 
unresponsive to suppression; this indi-
cates an important role of NFAT pro-
teins in T-cell homeostasis.
Type 1 Regulatory T Cells
Tr1 cells were first described in the 
murine system, and, in contrast to 
CD4+CD25+ Tregs, these cells were 
generated via repetitive stimulation of 
CD4+ TCR transgenic T cells with their 
cognate peptide in the presence of IL-
10 (Groux et al., 1997). Tr1 cells can 
inhibit T-cell responses in vitro and 
in vivo; for example, they can inhibit 
the development of colitis by exerting 
antigen-driven bystander suppression 
(Figure 2). Tr1 cells proliferate poorly 
after polyclonal or antigen-specific 
stimulation. Furthermore, Tr1 cells 
can regulate the activation of both 
naive and memory T cells and inhibit 
T cell-mediated responses to patho-
gens, alloantigens, and cancer (Foussat 
et al., 2003; Roncarolo et al., 2003). 
Several CD4+ T-cell sub-populations 
have been described as capable of 
inhibiting the response of other T cells. 
Tr1 cells secrete high amounts of IL-
10, moderate amounts of TGF-β, and 
some IL-5 as well as IFN-γ, but no IL-
2 or IL-4 (Groux et al., 1997). Tr1 cells 
were induced by repetitive stimulation 
of human CD4+ T cells in vitro in the 
presence of IL-10 (Levings and 
Roncarolo, 2000; Levings et al., 2001). 
In addition, culture supernatants of 
stimulated Tr1 cells were able to inhib-
it the allostimulatory capacity of DCs. 
Most of the immunosuppressive effects 
of Tr1 cells can be blocked by neu-
tralizing anti-IL-10 antibodies, which 
indicates that the suppressor effects 
induced by Tr1 cells are mainly medi-
ated by IL-10 (Roncarolo et al., 2001). 
More recently it was demonstrated that 
human Tr1 cells could be induced by 
treatment of resting CD4+ T cells with 
anti- CD3/anti-CD46 antibodies in the 
presence of IL-2 (Kemper et al., 2003). 
As CD46 is a complement regulator, 
these findings identified an endog-
enous receptor-mediated event that 
induced Tr1-cell differentiation and 
point to a previously unappreciated 
role of the complement system in mod-
ulating T cell-mediated responses.
There is recent evidence that Tr1 
cells play a role in controlling autoim-
mune reactions. Pemphigus vulgaris is 
primarily associated with circulating 
autoantibodies against the desmosome 
component desmoglein 3. Desmoglein 
3-specific Tr1 cells were identified that 
may maintain and restore natural toler-
ance against desmoglein 3 (Veldman 
et al., 2004). Desmoglein 3-responsive 
IL-10-secreting Tr1 cells were isolated 
from healthy carriers of the pemphi-
gus-associated HLA class II alleles 
DRB1*0402 and DQB1*0503 but were 
only rarely detected in pemphigus 
patients. In addition, it was shown that 
the growth of desmoglein 3-responsive 
Tr1 cells requires the presence of IL-2, 
and that they exert their desmoglein 
3-dependent inhibitory function by 
secreting IL-10 and TGF-β. Thus, these 
Tr1 cells may be critically involved in 
the maintenance and restoration of tol-
erance against desmoglein 3.
Other Types of Regulatory T Cells
Th3 cells have been identified in a 
model of EAE in which MBP is used to 
immunize mice by injection. However, 
MBP delivered by the oral route gener-
ates a population of T cells that inhib-
its that inflammatory reaction. Th3 
cells produce high concentrations of 
TGF-β and moderate amounts of IL-10 
and inhibit the development of auto-
immunity in several animal models 
(Weiner, 1997). Accordingly, Th3 cells 
from MBP-fed mice were able to sup-
press clinical EAE symptoms in vivo, 
and this suppression could be blocked 
by injections of anti-TGF-β antibodies. 
In addition, these cells inhibited the 
proliferation and cytokine release of 
MBP-specific Th1 clones in a TGF-β-
specific manner. The suppressor effects 
of Th3 cells are antigen-nonspecific 
and mediated as bystander inhibition, 
mainly via TGF-β. Accordingly, it was 
demonstrated that Th3 cells could sup-
press the activation of Th1-cell as well 
as Th2-cell clones (Weiner, 1997). Th3 
cells are therefore a unique subset of 
Th cells induced by orally fed antigens. 
It may be speculated that Tr1 and Th3 
cells derive from the same population 
and perhaps represent adaptive Tregs, 
as they have a similar phenotype and 
usually mediate their suppressive 
activities via the release of IL-10 and/
or TGF-β.
Besides CD4+ T cells, CD8+ T cells 
with suppressor activity have been 
detected, which were able to inhibit 
the development of EAE (Jiang et al., 
1992). CD8+ suppressor T cells abro-
gated the activation of encephalitogenic 
CD4+ Th1 cells. However, CD8+ sup-
pressor T cells required priming dur-
Teff Teff
Teff
Treg
Treg
IL-10
Treg
DC
DC
DC
DC
Figure 2. Mechanism of bystander suppression. 
Tregs that are activated by DCs in an antigen-
specific fashion release IL-10. Once released, 
IL-10 inhibits immune reactions not only against 
the initial antigen () but also against other 
antigens ( ,  ) in a nonspecific fashion.
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ing the first episode of EAE to regulate 
CD4+ T cells triggered by secondary 
MBP stimulation in vivo. As the suppres-
sor function of CD8+ T cells could be 
blocked by antibodies to the major his-
tocompatibility complex class Ib Qa-1 
molecule, it was suggested that perhaps 
the non-classical major histocompatibil-
ity complex class Ib pathway plays a role 
in restricting the suppression mediated 
by CD8+ T cells. Indeed, Qa-1–/– mice 
display severe EAE, which is associated 
with the escape of Qa-1–/– CD4+ T cells 
from CD8+ T-cell suppression (Hu et al., 
2004). Qa-1 is of limited polymorphism 
and is expressed on activated but not on 
resting T cells. Qa-1 has the potential 
to present foreign and self-peptides to 
CD8+ T cells, which indicates that Qa-1 
may serve as a target antigen for CD8+ 
T cells. Because Qa-1 self-peptide com-
plexes can bind to CD94-NKG2 recep-
tors on CD8+ T cells, CD8+ suppressor 
T cells may regulate T-cell responses via 
CD94-NKG2 receptors.
Parallel to the characterization of 
CD8+ suppressor T cells, CD8+CD28– 
T cells with regulatory activity have 
been identified (Cortesini et al., 2001; 
Liu et al., 1998). The investigation of 
CD8+CD28– Tregs from allospecific 
and xenospecific T-cell lines showed 
that these cells inhibited Th-cell pro-
liferation in a cell contact-dependent 
fashion that involved their interaction 
with APCs used for priming (Liu et al., 
1998). CD8+CD28– Tregs can block 
the upregulation of co-stimulatory 
molecules on APCs such as CD80, 
CD86, CD54 and CD58. Suppressor 
function could not be abrogated using 
neutralizing antibodies against IL-4, IL-
10, TGF-β, and CTLA-4. In contrast to 
the suppression of co-stimulatory mol-
ecules, CD8+CD28+ Treg have been 
demonstrated to upregulate the inhibi-
tory immunoglobulin-like transcript 
3 (ILT3) and ILT4 receptors on DCs 
(Chang et al., 2002). Taken together, 
these results suggest that CD8+CD28– 
Tregs suppress immune responses by 
directly interacting with DCs and ren-
dering these cells tolerogenic.
UV Radiation-Induced Regulatory T Cells
In a basic experiment in photoim-
munology, Toews et al. observed that 
topical application of contact allergens 
(haptens) onto UV-exposed skin does 
not result in sensitization but induces 
hapten-specific tolerance (Toews et 
al., 1980). This tolerance can be adop-
tively transferred into naive animals 
by intravenous injection of T cells into 
naive syngeneic recipients (Elmets et 
al., 1983). Although the transfer of 
UV-mediated suppression was subse-
quently shown in a convincing fashion 
in a variety of different immunologic in 
vivo models, the phenotypic character-
ization of the postulated UV-induced 
suppressor T cells was unsuccessful  
for many years; this contributed to the 
rejection of the concept of suppressor 
T cells in general immunology.
Shreedhar et al. were the first to suc-
ceed in isolating T-cell clones from UV-
exposed mice, which were sensitized 
with FITC (Shreedhar et al., 1998). 
Cloned cells were CD4+, CD8–, TCR-α/
β+, major histocompatibility complex-
restricted and specific for FITC. They 
produced IL-10, but not IL-4 or IFN-γ. 
These T cells blocked APC functions 
and IL-12 production, and, even more 
importantly, upon injection into naive 
recipients, suppressed the induction 
of contact hypersensitivity (CHS) 
against FITC.
UV-induced tolerance was observed 
in several immunologic models. In 
addition, a low- and a high-UV-dose 
regimen have been described, the 
first inducing local, the latter system-
ic immunosuppression (Beissert and 
Schwarz, 1999). Different Tregs with 
unique phenotypes may be involved 
in these systems. Currently best char-
acterized are the Tregs involved in the 
low-dose suppression of CHS. Cells 
transferring suppression in this model 
appear to belong to the CD4+CD25+ 
subtype (Schwarz et al., 2004); they 
express CTLA-4 (Schwarz et al., 2000), 
bind the lectin dectin-2 (Aragane et 
al., 2003) and, in contrast to the clas-
sical CD4+CD25+ T cells, release high 
amounts of IL-10 upon antigen-specific 
activation (Schwarz et al., 2000).
Whereas intravenous injection of 
T cells from UV-tolerized mice into 
naive animals renders the recipients 
unresponsive to the respective hap-
ten, intravenous injection of the very 
same cells into sensitized mice does 
not inhibit the CHS response in the 
Effect induced by Tregs
Homing receptors 
on Tregs required
Outcome
Inhibition of (auto)immunization
CD62L
Treg
Treg
Treg
1
2
T naiveDC
LYMPH NODE
SKIN
Epidermis
Dermis
Treg TeffTreg
Treg
Ag
LC
Treg
Teff
i.v.
Prevention of disease
Inhibition of elicitation
Immune reaction Immunization/sensitization Elicitation
Ligands for P-selectin (CD62P)
and E-selectin (CD62E)
Treatment of disease
LC
LC LC
Figure 3. Migration of Tregs. Because of expression of the lymph node homing receptor CD62L, UV-
induced Tregs, upon intravenous (i.v.) injection, migrate into the regional lymph nodes, where they 
inhibit sensitization by affecting naive T cells. (1) To inhibit ongoing immune reactions—for example, 
elicitation of contact hypersensitivity—Tregs have to migrate into the periphery (skin) to inhibit the 
activity of activated effector T cells (Teff). (2) Because UV-induced Tregs express lymph node homing 
receptors but not skin homing receptors, they migrate only into the lymph nodes but not into the skin 
upon i.v. injection. Thus, they inhibit only sensitization but not elicitation of contact hypersensitivity 
when injected i.v. Ag, antigen; LC, Langerhans cell.
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recipients (Glass et al., 1990). This led 
to the suggestion that Tregs inhibit the 
induction but not the elicitation of 
CHS and are inferior to effector T cells. 
However, when Tregs were injected 
into the area of challenge, in this case 
into the ears of sensitized mice, the 
elicitation of CHS was suppressed 
(Schwarz et al., 2004). This inhibition 
was hapten-specific. But when ears of 
oxazolone-sensitized mice were inject-
ed with dinitrofluorobenzene-specific 
Tregs and painted with dinitrofluoro-
benzene before challenge with oxazo-
lone, CHS was suppressed. Inhibition 
correlated with the local expression of 
IL-10. This observation is in accordance 
with the phenomenon of bystander 
suppression, initially described for Tr1 
cells (Figure 2). Together, this indicates 
that activation of UV-induced Tregs is 
hapten-specific but that, once acti-
vated, their suppressive activity is non-
specific. Depletion studies and FACS 
analysis revealed that UV-induced 
Tregs express the lymph node homing 
receptor L-selectin but not the ligands 
for the skin homing receptors E- and P-
selectin; this suggests that UV-induced 
Tregs, though able to inhibit effector 
T cells, do not suppress the elicitation 
of CHS upon intravenous injection, 
as they obviously do not migrate into 
the skin. Because of the capacity of 
bystander suppression, speculations 
exist about the therapeutic potential 
of Tregs that could be generated in 
response to antigens known to be pres-
ent in the target organ that are not nec-
essarily the precise antigen that drives 
the pathogenic response (Maloy and 
Powrie, 2001). However, these find-
ings indicate that this strategy will be 
successful only if the Tregs home to 
the target organs (Figure 3). The unique 
migratory behavior of Tregs might 
explain why, in the vast majority of in 
vivo studies, upon injection of Tregs 
only prevention, not cure, of various 
diseases has been observed.
IL-12 has been described by sever-
al groups as able to prevent the sup-
pression of CHS by UV, to prevent 
the development of Tregs and even to 
break UV-induced tolerance by yet 
unknown mechanisms (Beissert and 
Schwarz, 1999). UV-induced DNA 
damage has been recognized as the 
major molecular trigger of UV-mediat-
ed immunosuppression, as reduction of 
DNA damage is associated with a mit-
igation or loss of UV-induced immu-
nosuppression (Beissert and Schwarz, 
1999). The prevention of UV-induced 
immunosuppression by IL-12 may be 
due to its recently described capacity 
to reduce DNA damage via induction 
of DNA repair (Schwarz et al., 2002), 
as the preventive effect of IL-12 is not 
observed in DNA repair-deficient mice 
(Schwarz et al., 2005). UV-induced 
DNA damage appears to be also an 
important trigger for the induction of 
UV-induced Tregs, as reduction by 
IL-12 of Langerhans cells containing 
DNA damage in the regional lymph 
nodes prevented the development of 
Tregs. Again, in DNA repair-deficient 
mice, IL-12 failed to prevent the devel-
opment of UV-induced Tregs. In light 
of the fact that immature DCs induce 
Tregs (Jonuleit et al., 2000), these find-
ings may have identified another way 
to induce Tregs, via the presentation of 
antigens by UV-damaged DCs.
UV-induced Tregs also appear to 
play an important role in photocarcino-
genesis. Although their crucial role in 
supporting the development of UV-
induced skin tumors was described in 
the 1980s (Fisher and Kripke, 1982), 
these cells have been characterized 
only recently. They appear to belong 
to the natural killer T-cell lineage 
(Moodycliffe et al., 2000). After UV 
exposure, CD3+DX5+ cells, which 
produced high amounts of IL-4, sup-
pressed antigen-specific delayed-type 
hypersensitivity responses and antitu-
moral immunity against highly immu-
nogenic UV-induced skin tumors upon 
transfer in recipient mice.
Peripheral Homeostasis of Regulatory T 
Cells
Cytokines and co-stimulatory mol-
ecules are important in the homeo-
stasis of Tregs. Peripheral numbers of 
CD4+CD25+ T cells appear to criti-
cally depend on IL-2 (Malek et al., 
2002). Perhaps the expression of 
CD25 reflects the IL-2 dependency of 
Tregs. Several molecules of the B7 fam-
ily have been shown to control peri-
pheral numbers of CD4+CD25+ T cells 
as well (Lohr et al., 2003). CD86–/– 
mice, in contrast to CD80–/– animals, 
develop peripheral neuropathy, sug-
gesting that CD86–CD28/CTLA-4 
signaling maintains self-tolerance. 
Furthermore, CD28–/– mice have mark-
edly reduced numbers of CD4+CD25+ 
T cells (Tang et al., 2003). A new co-
receptor pathway within the B7 fam-
ily, ICOS–ICOS ligand signaling, 
plays a role in the development of 
asthma in mice. Mature pulmonary 
DCs in the bronchial lymph nodes 
of mice exposed to respiratory aller-
gens induced Tr1 cells, in a process 
that required ICOS–ICOS ligand sig-
naling (Akbari et al., 2002). Besides 
B7 family molecules, members of the 
tumor necrosis factor superfamily par-
ticipate in the maintenance of Tregs. 
CD40–/– as well as CD40L–/– mice have 
low numbers of CD4+CD25+ T cells 
(Kumanogoh et al., 2001). The closest 
homologue to CD40–CD40L within 
the tumor necrosis factor superfamily is 
the RANK–RANKL pathway. Indeed, in 
a transgenic model, blocking this path-
way with soluble RANK-Fc reduced 
the number of CD4+CD25+ T cells in 
pancreas-draining lymph nodes, result-
ing in diabetes (Green et al., 2002).
Because several of these signaling 
pathways are involved in the interac-
tion of APCs and T cells, DCs, as the 
professional APCs, have been investi-
gated in the context of CD4+CD25+ T 
cells. Interestingly, fully mature DCs 
are able to expand CD4+CD25+ T 
cells in vitro and in vivo (Yamazaki et 
al., 2003). Moreover, repetitive expo-
sure of conventional CD4+CD25– T 
cells to immature DCs induced T cells 
with regulatory function (Jonuleit et 
al., 2000). Therefore, DCs can induce 
and expand CD4+ Tregs. Immature 
DCs express CD205 (DEC-205), 
and antigens can be targeted to this 
receptor via binding to specific anti -
CD205 antibodies without induction 
of DC maturation. Antigen bound to 
CD205 on DCs was shown to induce 
CD4+CD25+ T cells (Mahnke et al., 
2003). These findings, together with 
the fact that Tregs maintain a partial-
ly activated phenotype, suggest that 
accumulation of these cells depends 
on continuous peripheral stimulation, 
perhaps via tissue antigens presented 
by resident APCs.
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Potential Therapeutic Use of Regulatory 
T Cells
The study of Tregs is progressing to 
a new level where the need to dem-
onstrate their existence has been 
replaced by the need to understand 
their biology so that therapeutic use 
will become a reality. The current liter-
ature suggests that natural CD4+CD25+ 
T cells function mainly to suppress 
immune responses to self, whereas 
adaptive subsets of Tregs primar-
ily maintain homeostatic control over 
various acquired immune responses. 
The ability to induce or expand Tregs 
in vitro or in vivo may have important 
implications in the field of autoimmu-
nity and inflammation. This concept 
is supported by the fact that impaired 
Treg function has been recently dem-
onstrated in multiple sclerosis patients 
(Viglietta et al., 2004). Another point 
of view is that most immunosuppres-
sive therapies may be used to reduce 
or eliminate activated T cells; however, 
such treatment may actually promote 
autoimmune responses by also deplet-
ing Tregs. An important advantage of 
using Tregs therapeutically would be 
that these cells can exert bystander 
suppression (Figure 2) in an antigen-
nonspecific fashion, which means that 
Tregs do not necessarily need to recog-
nize the antigen(s) that is the subject 
of immune attack. Furthermore, there 
is now clear evidence that function-
ally different subsets of Tregs exist in 
mice and humans (Table I). Differential 
expression of integrins on Treg sub-
sets appears to determine homing and 
migration of these subsets to distinct 
tissue such as the gut or skin (Figure 
3). Keratinocytes and Langerhans cells 
within the murine skin express E-cad-
herin, which is a ligand for the integ-
rin αEβ7, which again is expressed on 
30% of Tregs. Interestingly, αEβ7+ Tregs 
were found in cutaneous Leishmania 
major lesions of susceptible BALB/c 
mice (Suffia et al., 2005). It was, there-
fore, proposed that specialized subsets 
of Tregs migrate to distinct tissue, for 
example during inflammation, where 
they counteract activated or autoreac-
tive T cells and possibly also promote 
the induction of adaptive Tregs such 
as Tr1 and/or Th3 cells. It remains to 
be determined whether modulation of 
E-cadherin or induction of Treg-pro-
moting mediators such as TGF-β can be 
therapeutically utilized for treatment of 
human (skin) diseases. 
One important question that needs to 
be addressed in more detail is whether 
Tregs can also downregulate ongo-
ing (auto)immune responses. A critical 
issue in this respect is the migratory 
behavior of Tregs. When injected to 
prevent the manifestation of a disease, 
these cells appear to be required in 
the lymph nodes. The frequent expres-
sion of the lymph node homing recep-
tor CD62L on Tregs directs these cells 
into the lymph nodes. However, in 
order to downregulate already ongoing 
inflammatory responses, the Tregs are 
required to migrate into the periphery 
— in other words, into the areas where 
the inflammation takes place (Figure 3). 
For this, however, Tregs need to express 
homing receptors for the periphery. If 
the cells are injected directly into the 
area of inflammation, they perfectly 
suppress inflammation (Schwarz et 
al., 2004). Therefore, a crucial ques-
tion is whether it will be possible to 
manipulate Tregs in such a way that 
they express homing receptors for the 
periphery. In this context, it is important 
to mention that a dichotomy among 
Tregs has been described (Huehn et 
al., 2004). αE
–CD25+ cells expressed 
L-selectin and CCR7, enabling recir-
culation through lymphoid tissues. In 
contrast, positive subsets (CD25+ and 
CD25–) displayed an effector/memory 
phenotype, expressing high levels of 
E-selectin/P-selectin-binding ligands, 
multiple adhesion molecules, and 
receptors for inflammatory chemokines, 
and thus allowing efficient migration 
into inflamed sites. Accordingly, αE-
expressing cells were found to be the 
most potent suppressors of inflamma-
tory processes in disease models such 
as antigen-induced arthritis. In exten-
sion of this concept, perhaps the most 
important class of antigens to which the 
response will be inhibited by Tregs will 
be the antigens expressed by tumors. 
Temporary impairment of Treg function 
might facilitate vaccination protocols 
against both tumor-specific antigens 
and pathogens.
Another interesting issue in clini-
cal research is the isolation of Tregs 
with known specificity from autoim-
mune patients. Several autoantigens 
(in type I diabetes, multiple sclerosis, 
bullous skin disorders) are known, and 
therefore it is possible to sort autoan-
tigen-specific Tregs from either blood 
or lesions and to expand these cells 
in vitro for subsequent cellular immu-
notherapy. It has been recently shown 
in an experimental murine model that 
extracorporeal photopheresis, a pro-
cedure that is highly beneficial in the 
treatment of autoimmune diseases and 
graft-versus-host disease, might exert 
its immunosuppressive effects via the 
induction of Tregs (Maeda et al., 2005). 
All these issues will be the subject of 
fruitful investigations in the future. As 
interest in the field broadens, however, 
it is important that criteria be applied 
for the classification of Tregs, so that a 
focused body of knowledge will facili-
tate their therapeutic use.
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